21 research outputs found

    Overexpression of Eag1 potassium channels in clinical tumours

    Get PDF
    BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects

    Is CCL2 an Important Mediator of Mast Cell–Tumor Cell Interactions in Oral Squamous Cell Carcinoma?

    No full text
    In this study, we aimed to evaluate the influence of interactions between mast cells (MCs) and oral squamous cell carcinoma (OSCC) tumor cells on tumor proliferation and invasion rates and identify soluble factors mediating this crosstalk. To this end, MC/OSCC interactions were characterized using the human MC cell line LUVA and the human OSCC cell line PCI-13. The influence of an MC-conditioned (MCM) medium and MC/OSCC co-cultures on the proliferative and invasive properties of the tumor cells was investigated, and the most interesting soluble factors were identified by multiplex ELISA analysis. LUVA/PCI-13 co-cultures increased tumor cell proliferation significantly (p = 0.0164). MCM reduced PCI-13 cell invasion significantly (p = 0.0010). CC chemokine ligand 2 (CCL2) secretion could be detected in PCI-13 monocultures and be significantly (p = 0.0161) increased by LUVA/PCI-13 co-cultures. In summary, the MC/OSCC interaction influences tumor cell characteristics, and CCL2 could be identified as a possible mediator

    The regulation of angiogenesis by tissue cell-macrophage interactions

    No full text
    Angiogenesis is the physiological process where new blood vessels grow from existing ones, in order to replenish tissues suffering from inadequate blood supply. Perhaps the most studied angiogenic process occurs in solid tumors whose growing mass and expanding cells create a constant demand for additional supply of oxygen and nutrients for survival. However, other physiological and clinical conditions, such as wound healing, ischemic events, autoimmune and age-related diseases also involve angiogenesis. Angiogenesis is a well-structured process that begins when oxygen and nutrients are depleted, leading to the release of chemokines and growth factors that attract immune cells, particularly macrophages and endothelial cells to the site. Macrophages that are recruited to the site, as well as tissue cells and endothelial cells, secrete pro-angiogenic mediators that affect endothelial cells and promote angiogenesis. These mediators include growth factors such as vascular endothelial cell growth factor (VEGF), matrix metalloproteinases (MMPs), as well as low levels of mediators that are usually seen as pro-inflammatory but are pro-angiogenic when secreted in low levels (e.g. nitric oxide (NO) and TNFa). Thus, macrophages play a major role in angiogenesis. Macrophages exhibit high plasticity and are capable of shifting between different activation modes and functions according to their changing microenvironment. Small differences in the composition of activating factors (e.g. TLR ligands such as LPS, anti-inflammatory cytokines, ECM molecules) in the microenvironment may differently activate macrophages to yield classically activated macrophages (or M1 macrophages) that can kill pathogen and tumor cells, alternatively activated macrophages (or M2 macrophages) that secrete antiinflammatory cytokines, resolution macrophages (rM?) that are involved in the resolution of inflammation, or regulatory macrophages (e.g. Myeloid-Derived Suppressor Cells - MDSCs) that control the function of other immune cells. In fact, macrophages may be activated in a spectrum of subsets that may differently contribute to angiogenesis, and in particular non-classically activated macrophages such as tumor-associated macrophages (TAMs) and Tie2-expressing monocytes (TEMs) can secrete high amounts of pro-angiogenic factors (e.g. VEGF, MMPs) or low levels of pro-inflammatory mediators (e.g. NO or TNFa) resulting in pro-angiogenic effects. Although the importance of macrophages as major contributors and regulators of the angiogenic process is well documented, less is known about the interactions between macrophages and other cell types (e.g. tumor cells, normal epithelial cells, endothelial cells) that regulate angiogenesis. We still have only limited understanding which proteins or complexes mediate these interactions and whether they require cell-cell contact (e.g. through integrins) or soluble factors (e.g. the EGF-CSF-1 loop), which signaling pathways are triggered in each of the two corresponding cell types, and how this leads to secretion of pro- or antiangiogenic factors in the microenvironment. The regulation of such interactions and through them of angiogenesis, whether through post-translational modifications of proteins or via the involvement of microRNA, is still unclear. The goal of this Research Topic is to highlight these interactions and their regulation in the context of both physiological and pathological conditions

    Анализ Π²Ρ‹Π±ΠΎΡ€Π° мСста установки Π΄ΠΎΠΆΠΈΠΌΠ½ΠΎΠΉ компрСссорной станции Π½Π° ΠšΡˆΡƒΠΊΡΠΊΠΎΠΌ газокондСнсатном мСстороТдСнии (ΠšΠ°ΠΌΡ‡Π°Ρ‚ΡΠΊΠΈΠΉ ΠΊΡ€Π°ΠΉ)

    No full text
    ΠžΠ±ΡŠΠ΅ΠΊΡ‚ΠΎΠΌ исслСдования являСтся – Π²Ρ‹Π±ΠΎΡ€ мСста установки Π΄ΠΎΠΆΠΈΠΌΠ½ΠΎΠΉ компрСссорной станция Π½Π° мСстороТдСниС. ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ – ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π°Π½Π°Π»ΠΈΠ·Π° Π²Ρ‹Π±ΠΎΡ€Π° мСста установки Π΄ΠΎΠΆΠΈΠΌΠ½ΠΎΠΉ компрСссорной станции Π½Π° мСстороТдСнии. Π’ процСссС исслСдования – Π±Ρ‹Π»ΠΎ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ сравнСния Π΄Π²ΡƒΡ… ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Ρ… Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠ² мСсто располоТСния Π΄ΠΎΠΆΠΈΠΌΠ½ΠΎΠΉ компрСссорной станции с ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ наибольшСй эффСктивности Ρ€Π°Π±ΠΎΡ‚Ρ‹ тСхнологичСского процСсса. Π’ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ исслСдования – Π±Ρ‹Π»ΠΎ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎ сравнСниС Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠ² компримирования Π³Π°Π·Π° Π² зависимости ΠΎΡ‚ мСсторасполоТСния Π”ΠšΠ‘, ΠΏΡ€ΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½ ΠΏΠΎΠ΄Π±ΠΎΡ€ основного тСхнологичСского оборудования. По ΠΈΡ‚ΠΎΠ³Π°ΠΌ сравнСния Π΄Π²ΡƒΡ… Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠ² Π²Ρ‹Π±Ρ€Π°Π½ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡ€ΠΈΠ΅ΠΌΠ»Π΅ΠΌΠΎΠ΅ мСсто установки Π΄ΠΎΠΆΠΈΠΌΠ½ΠΎΠΉ компрСссорной станции с наибольшСй ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ Ρ€Π°Π±ΠΎΡ‚Ρ‹ тСхнологичСского процСсса.A research object is a choice of place of setting by a booster compressor the station on a deposit. An aim of work is realization of analysis of choice of place of setting of the booster compressor station on a deposit.In the process of research - comparisons of two offered variants were conducted place of location of the booster compressor station taking into account most efficiency of work of technological process. As a result of research - there was the conducted comparison of variants of compression gas depending on the location of BCS, the selection of basic technological equipment is produced. On results comparison of two variants the most acceptable place of setting of the booster compressor station is chosen with most efficiency of work of technological
    corecore